Global Highly Pathogenic PRRS Live Vaccine Market Growth 2026-2032
The global Highly Pathogenic PRRS Live Vaccine market size is predicted to grow from US$ 14.67 million in 2025 to US$ 19.71 million in 2032; it is expected to grow at a CAGR of 4.4% from 2026 to 2032.
Highly Pathogenic PRRS Live Vaccine is a modified live swine vaccine used for the prevention of highly pathogenic porcine reproductive and respiratory syndrome, also known as highly pathogenic porcine blue ear disease in China. Major commercial forms include monovalent vaccines based on JXA1-R, TJM-F92, GDr180, HuN4-F112 and related attenuated strains, as well as limited combination vaccines and heat-stabilized formulations containing a highly pathogenic PRRS component. Upstream inputs mainly include attenuated PRRSV seed strains, Marc-145 cells or other suitable cell substrates, culture media, serum or serum-free supplements, stabilizers, lyophilization protectants, diluents, glass vials, rubber stoppers, aluminum caps, labels and cold-chain packaging materials. Downstream customers mainly include integrated swine farming groups, breeding farms, commercial pig farms, veterinary drug distributors, animal disease control institutions and farm technical service providers. In 2025, global production capacity is estimated at around 286 million doses, with sales volume of about 207 million doses and an average ex-factory price of approximately USD 0.070?0.081 per dose; China accounts for the dominant share of both supply and demand, while overseas sales are limited and mainly related to export registration and use in nearby swine-producing markets. This is an approval- and batch-release-driven veterinary biologics segment with a relatively small single-product market size but strong disease-control relevance for pig farms. The estimated industry gross margin in 2025 is around 45%?60%, with leading producers benefiting from larger batch scale, established distribution channels and strain resources, while smaller suppliers face greater margin volatility due to batch size, channel discounts and cold-chain costs.
The current market is mainly supported by disease prevention demand in China's swine farming sector, with supply concentrated among companies that have veterinary biologics manufacturing qualifications, stable batch-release capabilities, mature cell culture processes and strong service capabilities for large-scale pig farms. This is not a globally widespread mass-market vaccine category, but a product segment closely linked to China's highly pathogenic porcine blue ear disease control system, veterinary drug registration framework and practical immunization programs in commercial swine production. Competition is not driven only by price and distribution channels, but also by product safety, batch consistency, field application experience, cold-chain assurance and the supplier's ability to support vaccination programs for farms with different herd health statuses. Demand shows clear structural differentiation. Large-scale pig farming groups and breeding farms place more emphasis on immunization safety, product consistency, strain relevance and long-term supply stability, so their purchasing decisions are generally more cautious. Commercial pig farms and small to medium-sized producers rely more on distributors, regional veterinary service networks and local disease pressure, and are relatively more price-sensitive. As swine farming becomes more consolidated, vaccine suppliers need to move beyond simple product sales and provide vaccination program design, antibody monitoring, herd stabilization management and integrated disease-control advice to strengthen customer stickiness and product value. Future development will focus more on safety improvement, process upgrading, combination vaccines and precision immunization. Traditional modified live vaccines still have advantages in immunogenicity, accumulated field experience and end-user acceptance, but their use will become more cautious in high-health-status farms and production systems pursuing PRRS elimination. Suspension culture can help improve production consistency and scale-up efficiency, heat-stabilized formulations can enhance storage and transportation stability, and combination vaccines can simplify immunization programs. As circulating PRRSV strains continue to evolve, companies also need stronger epidemiological monitoring and clinical validation capabilities to support product iteration and differentiated competition. The main growth drivers include the rising share of large-scale farming, continued investment in major swine disease control, more standardized veterinary vaccine regulation, improvement in farm biosecurity systems and stronger service capabilities among leading suppliers. Key constraints include hog price cycles affecting vaccination budgets, reduced use of live vaccines in some farms pursuing disease elimination, safety concerns related to modified live vaccines, uncertainty in protection caused by regional strain differences, and cost pressure from cold-chain logistics and batch quality control. Overall, this market is more stable and structurally adjusting than high-growth. Future growth will depend less on capacity expansion and more on product quality upgrades, customer concentration and stronger integrated service capabilities among leading companies.
LP Information, Inc. (LPI) ' newest research report, the ?Highly Pathogenic PRRS Live Vaccine Industry Forecast? looks at past sales and reviews total world Highly Pathogenic PRRS Live Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Highly Pathogenic PRRS Live Vaccine sales for 2026 through 2032. With Highly Pathogenic PRRS Live Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Highly Pathogenic PRRS Live Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Highly Pathogenic PRRS Live Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Highly Pathogenic PRRS Live Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Highly Pathogenic PRRS Live Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Highly Pathogenic PRRS Live Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Highly Pathogenic PRRS Live Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Highly Pathogenic PRRS Live Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Highly Pathogenic PRRS Live Vaccine market?
What factors are driving Highly Pathogenic PRRS Live Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Highly Pathogenic PRRS Live Vaccine market opportunities vary by end market size?
How does Highly Pathogenic PRRS Live Vaccine break out by Type, by Application?
Highly Pathogenic PRRS Live Vaccine is a modified live swine vaccine used for the prevention of highly pathogenic porcine reproductive and respiratory syndrome, also known as highly pathogenic porcine blue ear disease in China. Major commercial forms include monovalent vaccines based on JXA1-R, TJM-F92, GDr180, HuN4-F112 and related attenuated strains, as well as limited combination vaccines and heat-stabilized formulations containing a highly pathogenic PRRS component. Upstream inputs mainly include attenuated PRRSV seed strains, Marc-145 cells or other suitable cell substrates, culture media, serum or serum-free supplements, stabilizers, lyophilization protectants, diluents, glass vials, rubber stoppers, aluminum caps, labels and cold-chain packaging materials. Downstream customers mainly include integrated swine farming groups, breeding farms, commercial pig farms, veterinary drug distributors, animal disease control institutions and farm technical service providers. In 2025, global production capacity is estimated at around 286 million doses, with sales volume of about 207 million doses and an average ex-factory price of approximately USD 0.070?0.081 per dose; China accounts for the dominant share of both supply and demand, while overseas sales are limited and mainly related to export registration and use in nearby swine-producing markets. This is an approval- and batch-release-driven veterinary biologics segment with a relatively small single-product market size but strong disease-control relevance for pig farms. The estimated industry gross margin in 2025 is around 45%?60%, with leading producers benefiting from larger batch scale, established distribution channels and strain resources, while smaller suppliers face greater margin volatility due to batch size, channel discounts and cold-chain costs.
The current market is mainly supported by disease prevention demand in China's swine farming sector, with supply concentrated among companies that have veterinary biologics manufacturing qualifications, stable batch-release capabilities, mature cell culture processes and strong service capabilities for large-scale pig farms. This is not a globally widespread mass-market vaccine category, but a product segment closely linked to China's highly pathogenic porcine blue ear disease control system, veterinary drug registration framework and practical immunization programs in commercial swine production. Competition is not driven only by price and distribution channels, but also by product safety, batch consistency, field application experience, cold-chain assurance and the supplier's ability to support vaccination programs for farms with different herd health statuses. Demand shows clear structural differentiation. Large-scale pig farming groups and breeding farms place more emphasis on immunization safety, product consistency, strain relevance and long-term supply stability, so their purchasing decisions are generally more cautious. Commercial pig farms and small to medium-sized producers rely more on distributors, regional veterinary service networks and local disease pressure, and are relatively more price-sensitive. As swine farming becomes more consolidated, vaccine suppliers need to move beyond simple product sales and provide vaccination program design, antibody monitoring, herd stabilization management and integrated disease-control advice to strengthen customer stickiness and product value. Future development will focus more on safety improvement, process upgrading, combination vaccines and precision immunization. Traditional modified live vaccines still have advantages in immunogenicity, accumulated field experience and end-user acceptance, but their use will become more cautious in high-health-status farms and production systems pursuing PRRS elimination. Suspension culture can help improve production consistency and scale-up efficiency, heat-stabilized formulations can enhance storage and transportation stability, and combination vaccines can simplify immunization programs. As circulating PRRSV strains continue to evolve, companies also need stronger epidemiological monitoring and clinical validation capabilities to support product iteration and differentiated competition. The main growth drivers include the rising share of large-scale farming, continued investment in major swine disease control, more standardized veterinary vaccine regulation, improvement in farm biosecurity systems and stronger service capabilities among leading suppliers. Key constraints include hog price cycles affecting vaccination budgets, reduced use of live vaccines in some farms pursuing disease elimination, safety concerns related to modified live vaccines, uncertainty in protection caused by regional strain differences, and cost pressure from cold-chain logistics and batch quality control. Overall, this market is more stable and structurally adjusting than high-growth. Future growth will depend less on capacity expansion and more on product quality upgrades, customer concentration and stronger integrated service capabilities among leading companies.
LP Information, Inc. (LPI) ' newest research report, the ?Highly Pathogenic PRRS Live Vaccine Industry Forecast? looks at past sales and reviews total world Highly Pathogenic PRRS Live Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Highly Pathogenic PRRS Live Vaccine sales for 2026 through 2032. With Highly Pathogenic PRRS Live Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Highly Pathogenic PRRS Live Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Highly Pathogenic PRRS Live Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Highly Pathogenic PRRS Live Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Highly Pathogenic PRRS Live Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Highly Pathogenic PRRS Live Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Highly Pathogenic PRRS Live Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Highly Pathogenic PRRS Live Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- JXA1-R Strain Live Vaccine
- TJM-F92 Strain Live Vaccine
- GDr180 Strain Live Vaccine
- Others
- Monovalent Live Vaccine
- Combination Live Vaccine
- Small Pack (Below 20 Doses per Vial)
- Medium Pack (20?50 Doses per Vial)
- Large Pack (Above 50 Doses per Vial)
- Large-scale Integrated Pig Farming Groups
- Breeding and Multiplier Farms
- Animal Disease Control Institutions
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Dahuanong Animal Health
- Zoetis
- Jilin Teyan Biotechnology
- Qingdao Yebio Bioengineering
- Sinopharm Yangzhou Vac Biological Engineering
- Pulike Biological Engineering
- Guangdong WINSUN Bio-pharmaceutical
- Sinovetah Biological Pharmaceutical
- TECON Pharmaceutical
- Harbin Veken Biotechnology
- CAHIC
- Huapai Biotechnology Group
- Chengdu Shiji Biological Pharmaceutical
- Jilin Heyuan Biotechnology
What is the 10-year outlook for the global Highly Pathogenic PRRS Live Vaccine market?
What factors are driving Highly Pathogenic PRRS Live Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Highly Pathogenic PRRS Live Vaccine market opportunities vary by end market size?
How does Highly Pathogenic PRRS Live Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Highly Pathogenic PRRS Live Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Highly Pathogenic PRRS Live Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Highly Pathogenic PRRS Live Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Highly Pathogenic PRRS Live Vaccine Segment by Type
2.2.1 JXA1-R Strain Live Vaccine
2.2.2 TJM-F92 Strain Live Vaccine
2.2.3 GDr180 Strain Live Vaccine
2.2.4 Others
2.2.5 Highly Pathogenic PRRS Live Vaccine Sales by Type
2.2.5.1 Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Type (2021-2026)
2.2.5.2 Global Highly Pathogenic PRRS Live Vaccine Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Highly Pathogenic PRRS Live Vaccine Sale Price by Type (2021-2026)
2.3 Highly Pathogenic PRRS Live Vaccine Segment by Product Combination
2.3.1 Monovalent Live Vaccine
2.3.2 Combination Live Vaccine
2.3.3 Highly Pathogenic PRRS Live Vaccine Sales by Product Combination
2.3.3.1 Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Product Combination (2021-2026)
2.3.3.2 Global Highly Pathogenic PRRS Live Vaccine Revenue and Market Share by Product Combination (2021-2026)
2.3.3.3 Global Highly Pathogenic PRRS Live Vaccine Sale Price by Product Combination (2021-2026)
2.4 Highly Pathogenic PRRS Live Vaccine Segment by Dose Pack Size
2.4.1 Small Pack (Below 20 Doses per Vial)
2.4.2 Medium Pack (20?50 Doses per Vial)
2.4.3 Large Pack (Above 50 Doses per Vial)
2.4.4 Highly Pathogenic PRRS Live Vaccine Sales by Dose Pack Size
2.4.4.1 Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Dose Pack Size (2021-2026)
2.4.4.2 Global Highly Pathogenic PRRS Live Vaccine Revenue and Market Share by Dose Pack Size (2021-2026)
2.4.4.3 Global Highly Pathogenic PRRS Live Vaccine Sale Price by Dose Pack Size (2021-2026)
2.5 Highly Pathogenic PRRS Live Vaccine Segment by Application
2.5.1 Large-scale Integrated Pig Farming Groups
2.5.2 Breeding and Multiplier Farms
2.5.3 Animal Disease Control Institutions
2.5.4 Others
2.5.5 Highly Pathogenic PRRS Live Vaccine Sales by Application
2.5.5.1 Global Highly Pathogenic PRRS Live Vaccine Sale Market Share by Application (2021-2026)
2.5.5.2 Global Highly Pathogenic PRRS Live Vaccine Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global Highly Pathogenic PRRS Live Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Highly Pathogenic PRRS Live Vaccine Breakdown Data by Company
3.1.1 Global Highly Pathogenic PRRS Live Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Highly Pathogenic PRRS Live Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Highly Pathogenic PRRS Live Vaccine Revenue by Company (2021-2026)
3.2.2 Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Highly Pathogenic PRRS Live Vaccine Sale Price by Company
3.4 Key Manufacturers Highly Pathogenic PRRS Live Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Highly Pathogenic PRRS Live Vaccine Product Location Distribution
3.4.2 Players Highly Pathogenic PRRS Live Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR HIGHLY PATHOGENIC PRRS LIVE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Highly Pathogenic PRRS Live Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Highly Pathogenic PRRS Live Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Highly Pathogenic PRRS Live Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Highly Pathogenic PRRS Live Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Highly Pathogenic PRRS Live Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Highly Pathogenic PRRS Live Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Highly Pathogenic PRRS Live Vaccine Sales Growth
4.4 APAC Highly Pathogenic PRRS Live Vaccine Sales Growth
4.5 Europe Highly Pathogenic PRRS Live Vaccine Sales Growth
4.6 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Growth
5 AMERICAS
5.1 Americas Highly Pathogenic PRRS Live Vaccine Sales by Country
5.1.1 Americas Highly Pathogenic PRRS Live Vaccine Sales by Country (2021-2026)
5.1.2 Americas Highly Pathogenic PRRS Live Vaccine Revenue by Country (2021-2026)
5.2 Americas Highly Pathogenic PRRS Live Vaccine Sales by Type (2021-2026)
5.3 Americas Highly Pathogenic PRRS Live Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Highly Pathogenic PRRS Live Vaccine Sales by Region
6.1.1 APAC Highly Pathogenic PRRS Live Vaccine Sales by Region (2021-2026)
6.1.2 APAC Highly Pathogenic PRRS Live Vaccine Revenue by Region (2021-2026)
6.2 APAC Highly Pathogenic PRRS Live Vaccine Sales by Type (2021-2026)
6.3 APAC Highly Pathogenic PRRS Live Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Highly Pathogenic PRRS Live Vaccine by Country
7.1.1 Europe Highly Pathogenic PRRS Live Vaccine Sales by Country (2021-2026)
7.1.2 Europe Highly Pathogenic PRRS Live Vaccine Revenue by Country (2021-2026)
7.2 Europe Highly Pathogenic PRRS Live Vaccine Sales by Type (2021-2026)
7.3 Europe Highly Pathogenic PRRS Live Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Highly Pathogenic PRRS Live Vaccine by Country
8.1.1 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Highly Pathogenic PRRS Live Vaccine
10.3 Manufacturing Process Analysis of Highly Pathogenic PRRS Live Vaccine
10.4 Industry Chain Structure of Highly Pathogenic PRRS Live Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Highly Pathogenic PRRS Live Vaccine Distributors
11.3 Highly Pathogenic PRRS Live Vaccine Customer
12 WORLD FORECAST REVIEW FOR HIGHLY PATHOGENIC PRRS LIVE VACCINE BY GEOGRAPHIC REGION
12.1 Global Highly Pathogenic PRRS Live Vaccine Market Size Forecast by Region
12.1.1 Global Highly Pathogenic PRRS Live Vaccine Forecast by Region (2027-2032)
12.1.2 Global Highly Pathogenic PRRS Live Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Highly Pathogenic PRRS Live Vaccine Forecast by Type (2027-2032)
12.7 Global Highly Pathogenic PRRS Live Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Dahuanong Animal Health
13.1.1 Dahuanong Animal Health Company Information
13.1.2 Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.1.3 Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Dahuanong Animal Health Main Business Overview
13.1.5 Dahuanong Animal Health Latest Developments
13.2 Zoetis
13.2.1 Zoetis Company Information
13.2.2 Zoetis Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.2.3 Zoetis Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Zoetis Main Business Overview
13.2.5 Zoetis Latest Developments
13.3 Jilin Teyan Biotechnology
13.3.1 Jilin Teyan Biotechnology Company Information
13.3.2 Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.3.3 Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Jilin Teyan Biotechnology Main Business Overview
13.3.5 Jilin Teyan Biotechnology Latest Developments
13.4 Qingdao Yebio Bioengineering
13.4.1 Qingdao Yebio Bioengineering Company Information
13.4.2 Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.4.3 Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Qingdao Yebio Bioengineering Main Business Overview
13.4.5 Qingdao Yebio Bioengineering Latest Developments
13.5 Sinopharm Yangzhou Vac Biological Engineering
13.5.1 Sinopharm Yangzhou Vac Biological Engineering Company Information
13.5.2 Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.5.3 Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sinopharm Yangzhou Vac Biological Engineering Main Business Overview
13.5.5 Sinopharm Yangzhou Vac Biological Engineering Latest Developments
13.6 Pulike Biological Engineering
13.6.1 Pulike Biological Engineering Company Information
13.6.2 Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.6.3 Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Pulike Biological Engineering Main Business Overview
13.6.5 Pulike Biological Engineering Latest Developments
13.7 Guangdong WINSUN Bio-pharmaceutical
13.7.1 Guangdong WINSUN Bio-pharmaceutical Company Information
13.7.2 Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.7.3 Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Guangdong WINSUN Bio-pharmaceutical Main Business Overview
13.7.5 Guangdong WINSUN Bio-pharmaceutical Latest Developments
13.8 Sinovetah Biological Pharmaceutical
13.8.1 Sinovetah Biological Pharmaceutical Company Information
13.8.2 Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.8.3 Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Sinovetah Biological Pharmaceutical Main Business Overview
13.8.5 Sinovetah Biological Pharmaceutical Latest Developments
13.9 TECON Pharmaceutical
13.9.1 TECON Pharmaceutical Company Information
13.9.2 TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.9.3 TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 TECON Pharmaceutical Main Business Overview
13.9.5 TECON Pharmaceutical Latest Developments
13.10 Harbin Veken Biotechnology
13.10.1 Harbin Veken Biotechnology Company Information
13.10.2 Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.10.3 Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Harbin Veken Biotechnology Main Business Overview
13.10.5 Harbin Veken Biotechnology Latest Developments
13.11 CAHIC
13.11.1 CAHIC Company Information
13.11.2 CAHIC Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.11.3 CAHIC Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 CAHIC Main Business Overview
13.11.5 CAHIC Latest Developments
13.12 Huapai Biotechnology Group
13.12.1 Huapai Biotechnology Group Company Information
13.12.2 Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.12.3 Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Huapai Biotechnology Group Main Business Overview
13.12.5 Huapai Biotechnology Group Latest Developments
13.13 Chengdu Shiji Biological Pharmaceutical
13.13.1 Chengdu Shiji Biological Pharmaceutical Company Information
13.13.2 Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.13.3 Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Chengdu Shiji Biological Pharmaceutical Main Business Overview
13.13.5 Chengdu Shiji Biological Pharmaceutical Latest Developments
13.14 Jilin Heyuan Biotechnology
13.14.1 Jilin Heyuan Biotechnology Company Information
13.14.2 Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.14.3 Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Jilin Heyuan Biotechnology Main Business Overview
13.14.5 Jilin Heyuan Biotechnology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Highly Pathogenic PRRS Live Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Highly Pathogenic PRRS Live Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Highly Pathogenic PRRS Live Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Highly Pathogenic PRRS Live Vaccine Segment by Type
2.2.1 JXA1-R Strain Live Vaccine
2.2.2 TJM-F92 Strain Live Vaccine
2.2.3 GDr180 Strain Live Vaccine
2.2.4 Others
2.2.5 Highly Pathogenic PRRS Live Vaccine Sales by Type
2.2.5.1 Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Type (2021-2026)
2.2.5.2 Global Highly Pathogenic PRRS Live Vaccine Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Highly Pathogenic PRRS Live Vaccine Sale Price by Type (2021-2026)
2.3 Highly Pathogenic PRRS Live Vaccine Segment by Product Combination
2.3.1 Monovalent Live Vaccine
2.3.2 Combination Live Vaccine
2.3.3 Highly Pathogenic PRRS Live Vaccine Sales by Product Combination
2.3.3.1 Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Product Combination (2021-2026)
2.3.3.2 Global Highly Pathogenic PRRS Live Vaccine Revenue and Market Share by Product Combination (2021-2026)
2.3.3.3 Global Highly Pathogenic PRRS Live Vaccine Sale Price by Product Combination (2021-2026)
2.4 Highly Pathogenic PRRS Live Vaccine Segment by Dose Pack Size
2.4.1 Small Pack (Below 20 Doses per Vial)
2.4.2 Medium Pack (20?50 Doses per Vial)
2.4.3 Large Pack (Above 50 Doses per Vial)
2.4.4 Highly Pathogenic PRRS Live Vaccine Sales by Dose Pack Size
2.4.4.1 Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Dose Pack Size (2021-2026)
2.4.4.2 Global Highly Pathogenic PRRS Live Vaccine Revenue and Market Share by Dose Pack Size (2021-2026)
2.4.4.3 Global Highly Pathogenic PRRS Live Vaccine Sale Price by Dose Pack Size (2021-2026)
2.5 Highly Pathogenic PRRS Live Vaccine Segment by Application
2.5.1 Large-scale Integrated Pig Farming Groups
2.5.2 Breeding and Multiplier Farms
2.5.3 Animal Disease Control Institutions
2.5.4 Others
2.5.5 Highly Pathogenic PRRS Live Vaccine Sales by Application
2.5.5.1 Global Highly Pathogenic PRRS Live Vaccine Sale Market Share by Application (2021-2026)
2.5.5.2 Global Highly Pathogenic PRRS Live Vaccine Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global Highly Pathogenic PRRS Live Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Highly Pathogenic PRRS Live Vaccine Breakdown Data by Company
3.1.1 Global Highly Pathogenic PRRS Live Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Highly Pathogenic PRRS Live Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Highly Pathogenic PRRS Live Vaccine Revenue by Company (2021-2026)
3.2.2 Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Highly Pathogenic PRRS Live Vaccine Sale Price by Company
3.4 Key Manufacturers Highly Pathogenic PRRS Live Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Highly Pathogenic PRRS Live Vaccine Product Location Distribution
3.4.2 Players Highly Pathogenic PRRS Live Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR HIGHLY PATHOGENIC PRRS LIVE VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Highly Pathogenic PRRS Live Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Highly Pathogenic PRRS Live Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Highly Pathogenic PRRS Live Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Highly Pathogenic PRRS Live Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Highly Pathogenic PRRS Live Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Highly Pathogenic PRRS Live Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Highly Pathogenic PRRS Live Vaccine Sales Growth
4.4 APAC Highly Pathogenic PRRS Live Vaccine Sales Growth
4.5 Europe Highly Pathogenic PRRS Live Vaccine Sales Growth
4.6 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Growth
5 AMERICAS
5.1 Americas Highly Pathogenic PRRS Live Vaccine Sales by Country
5.1.1 Americas Highly Pathogenic PRRS Live Vaccine Sales by Country (2021-2026)
5.1.2 Americas Highly Pathogenic PRRS Live Vaccine Revenue by Country (2021-2026)
5.2 Americas Highly Pathogenic PRRS Live Vaccine Sales by Type (2021-2026)
5.3 Americas Highly Pathogenic PRRS Live Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Highly Pathogenic PRRS Live Vaccine Sales by Region
6.1.1 APAC Highly Pathogenic PRRS Live Vaccine Sales by Region (2021-2026)
6.1.2 APAC Highly Pathogenic PRRS Live Vaccine Revenue by Region (2021-2026)
6.2 APAC Highly Pathogenic PRRS Live Vaccine Sales by Type (2021-2026)
6.3 APAC Highly Pathogenic PRRS Live Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Highly Pathogenic PRRS Live Vaccine by Country
7.1.1 Europe Highly Pathogenic PRRS Live Vaccine Sales by Country (2021-2026)
7.1.2 Europe Highly Pathogenic PRRS Live Vaccine Revenue by Country (2021-2026)
7.2 Europe Highly Pathogenic PRRS Live Vaccine Sales by Type (2021-2026)
7.3 Europe Highly Pathogenic PRRS Live Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Highly Pathogenic PRRS Live Vaccine by Country
8.1.1 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Highly Pathogenic PRRS Live Vaccine
10.3 Manufacturing Process Analysis of Highly Pathogenic PRRS Live Vaccine
10.4 Industry Chain Structure of Highly Pathogenic PRRS Live Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Highly Pathogenic PRRS Live Vaccine Distributors
11.3 Highly Pathogenic PRRS Live Vaccine Customer
12 WORLD FORECAST REVIEW FOR HIGHLY PATHOGENIC PRRS LIVE VACCINE BY GEOGRAPHIC REGION
12.1 Global Highly Pathogenic PRRS Live Vaccine Market Size Forecast by Region
12.1.1 Global Highly Pathogenic PRRS Live Vaccine Forecast by Region (2027-2032)
12.1.2 Global Highly Pathogenic PRRS Live Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Highly Pathogenic PRRS Live Vaccine Forecast by Type (2027-2032)
12.7 Global Highly Pathogenic PRRS Live Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Dahuanong Animal Health
13.1.1 Dahuanong Animal Health Company Information
13.1.2 Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.1.3 Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Dahuanong Animal Health Main Business Overview
13.1.5 Dahuanong Animal Health Latest Developments
13.2 Zoetis
13.2.1 Zoetis Company Information
13.2.2 Zoetis Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.2.3 Zoetis Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Zoetis Main Business Overview
13.2.5 Zoetis Latest Developments
13.3 Jilin Teyan Biotechnology
13.3.1 Jilin Teyan Biotechnology Company Information
13.3.2 Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.3.3 Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Jilin Teyan Biotechnology Main Business Overview
13.3.5 Jilin Teyan Biotechnology Latest Developments
13.4 Qingdao Yebio Bioengineering
13.4.1 Qingdao Yebio Bioengineering Company Information
13.4.2 Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.4.3 Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Qingdao Yebio Bioengineering Main Business Overview
13.4.5 Qingdao Yebio Bioengineering Latest Developments
13.5 Sinopharm Yangzhou Vac Biological Engineering
13.5.1 Sinopharm Yangzhou Vac Biological Engineering Company Information
13.5.2 Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.5.3 Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sinopharm Yangzhou Vac Biological Engineering Main Business Overview
13.5.5 Sinopharm Yangzhou Vac Biological Engineering Latest Developments
13.6 Pulike Biological Engineering
13.6.1 Pulike Biological Engineering Company Information
13.6.2 Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.6.3 Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Pulike Biological Engineering Main Business Overview
13.6.5 Pulike Biological Engineering Latest Developments
13.7 Guangdong WINSUN Bio-pharmaceutical
13.7.1 Guangdong WINSUN Bio-pharmaceutical Company Information
13.7.2 Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.7.3 Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Guangdong WINSUN Bio-pharmaceutical Main Business Overview
13.7.5 Guangdong WINSUN Bio-pharmaceutical Latest Developments
13.8 Sinovetah Biological Pharmaceutical
13.8.1 Sinovetah Biological Pharmaceutical Company Information
13.8.2 Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.8.3 Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Sinovetah Biological Pharmaceutical Main Business Overview
13.8.5 Sinovetah Biological Pharmaceutical Latest Developments
13.9 TECON Pharmaceutical
13.9.1 TECON Pharmaceutical Company Information
13.9.2 TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.9.3 TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 TECON Pharmaceutical Main Business Overview
13.9.5 TECON Pharmaceutical Latest Developments
13.10 Harbin Veken Biotechnology
13.10.1 Harbin Veken Biotechnology Company Information
13.10.2 Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.10.3 Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Harbin Veken Biotechnology Main Business Overview
13.10.5 Harbin Veken Biotechnology Latest Developments
13.11 CAHIC
13.11.1 CAHIC Company Information
13.11.2 CAHIC Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.11.3 CAHIC Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 CAHIC Main Business Overview
13.11.5 CAHIC Latest Developments
13.12 Huapai Biotechnology Group
13.12.1 Huapai Biotechnology Group Company Information
13.12.2 Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.12.3 Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Huapai Biotechnology Group Main Business Overview
13.12.5 Huapai Biotechnology Group Latest Developments
13.13 Chengdu Shiji Biological Pharmaceutical
13.13.1 Chengdu Shiji Biological Pharmaceutical Company Information
13.13.2 Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.13.3 Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Chengdu Shiji Biological Pharmaceutical Main Business Overview
13.13.5 Chengdu Shiji Biological Pharmaceutical Latest Developments
13.14 Jilin Heyuan Biotechnology
13.14.1 Jilin Heyuan Biotechnology Company Information
13.14.2 Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
13.14.3 Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Jilin Heyuan Biotechnology Main Business Overview
13.14.5 Jilin Heyuan Biotechnology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Highly Pathogenic PRRS Live Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Highly Pathogenic PRRS Live Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of JXA1-R Strain Live Vaccine
Table 4. Major Players of TJM-F92 Strain Live Vaccine
Table 5. Major Players of GDr180 Strain Live Vaccine
Table 6. Major Players of Others
Table 7. Global Highly Pathogenic PRRS Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 8. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Type (2021-2026)
Table 9. Global Highly Pathogenic PRRS Live Vaccine Revenue by Type (2021-2026) & ($ million)
Table 10. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Type (2021-2026)
Table 11. Global Highly Pathogenic PRRS Live Vaccine Sale Price by Type (2021-2026) & (US$/Dose)
Table 12. Major Players of Monovalent Live Vaccine
Table 13. Major Players of Combination Live Vaccine
Table 14. Global Highly Pathogenic PRRS Live Vaccine Sales by Product Combination (2021-2026) & (K Dose)
Table 15. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Product Combination (2021-2026)
Table 16. Global Highly Pathogenic PRRS Live Vaccine Revenue by Product Combination (2021-2026) & ($ million)
Table 17. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Product Combination (2021-2026)
Table 18. Global Highly Pathogenic PRRS Live Vaccine Sale Price by Product Combination (2021-2026) & (US$/Dose)
Table 19. Major Players of Small Pack (Below 20 Doses per Vial)
Table 20. Major Players of Medium Pack (20?50 Doses per Vial)
Table 21. Major Players of Large Pack (Above 50 Doses per Vial)
Table 22. Global Highly Pathogenic PRRS Live Vaccine Sales by Dose Pack Size (2021-2026) & (K Dose)
Table 23. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Dose Pack Size (2021-2026)
Table 24. Global Highly Pathogenic PRRS Live Vaccine Revenue by Dose Pack Size (2021-2026) & ($ million)
Table 25. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
Table 26. Global Highly Pathogenic PRRS Live Vaccine Sale Price by Dose Pack Size (2021-2026) & (US$/Dose)
Table 27. Global Highly Pathogenic PRRS Live Vaccine Sale by Application (2021-2026) & (K Dose)
Table 28. Global Highly Pathogenic PRRS Live Vaccine Sale Market Share by Application (2021-2026)
Table 29. Global Highly Pathogenic PRRS Live Vaccine Revenue by Application (2021-2026) & ($ million)
Table 30. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Application (2021-2026)
Table 31. Global Highly Pathogenic PRRS Live Vaccine Sale Price by Application (2021-2026) & (US$/Dose)
Table 32. Global Highly Pathogenic PRRS Live Vaccine Sales by Company (2021-2026) & (K Dose)
Table 33. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Company (2021-2026)
Table 34. Global Highly Pathogenic PRRS Live Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 35. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Company (2021-2026)
Table 36. Global Highly Pathogenic PRRS Live Vaccine Sale Price by Company (2021-2026) & (US$/Dose)
Table 37. Key Manufacturers Highly Pathogenic PRRS Live Vaccine Producing Area Distribution and Sales Area
Table 38. Players Highly Pathogenic PRRS Live Vaccine Products Offered
Table 39. Highly Pathogenic PRRS Live Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 40. New Products and Potential Entrants
Table 41. Market M&A Activity & Strategy
Table 42. Global Highly Pathogenic PRRS Live Vaccine Sales by Geographic Region (2021-2026) & (K Dose)
Table 43. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share Geographic Region (2021-2026)
Table 44. Global Highly Pathogenic PRRS Live Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 45. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 46. Global Highly Pathogenic PRRS Live Vaccine Sales by Country/Region (2021-2026) & (K Dose)
Table 47. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Country/Region (2021-2026)
Table 48. Global Highly Pathogenic PRRS Live Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 49. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 50. Americas Highly Pathogenic PRRS Live Vaccine Sales by Country (2021-2026) & (K Dose)
Table 51. Americas Highly Pathogenic PRRS Live Vaccine Sales Market Share by Country (2021-2026)
Table 52. Americas Highly Pathogenic PRRS Live Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 53. Americas Highly Pathogenic PRRS Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 54. Americas Highly Pathogenic PRRS Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 55. APAC Highly Pathogenic PRRS Live Vaccine Sales by Region (2021-2026) & (K Dose)
Table 56. APAC Highly Pathogenic PRRS Live Vaccine Sales Market Share by Region (2021-2026)
Table 57. APAC Highly Pathogenic PRRS Live Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 58. APAC Highly Pathogenic PRRS Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 59. APAC Highly Pathogenic PRRS Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 60. Europe Highly Pathogenic PRRS Live Vaccine Sales by Country (2021-2026) & (K Dose)
Table 61. Europe Highly Pathogenic PRRS Live Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 62. Europe Highly Pathogenic PRRS Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 63. Europe Highly Pathogenic PRRS Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 64. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales by Country (2021-2026) & (K Dose)
Table 65. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Country (2021-2026)
Table 66. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 67. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 68. Key Market Drivers & Growth Opportunities of Highly Pathogenic PRRS Live Vaccine
Table 69. Key Market Challenges & Risks of Highly Pathogenic PRRS Live Vaccine
Table 70. Key Industry Trends of Highly Pathogenic PRRS Live Vaccine
Table 71. Highly Pathogenic PRRS Live Vaccine Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. Highly Pathogenic PRRS Live Vaccine Distributors List
Table 74. Highly Pathogenic PRRS Live Vaccine Customer List
Table 75. Global Highly Pathogenic PRRS Live Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 76. Global Highly Pathogenic PRRS Live Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 77. Americas Highly Pathogenic PRRS Live Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 78. Americas Highly Pathogenic PRRS Live Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 79. APAC Highly Pathogenic PRRS Live Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 80. APAC Highly Pathogenic PRRS Live Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Europe Highly Pathogenic PRRS Live Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 82. Europe Highly Pathogenic PRRS Live Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 84. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 85. Global Highly Pathogenic PRRS Live Vaccine Sales Forecast by Type (2027-2032) & (K Dose)
Table 86. Global Highly Pathogenic PRRS Live Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 87. Global Highly Pathogenic PRRS Live Vaccine Sales Forecast by Application (2027-2032) & (K Dose)
Table 88. Global Highly Pathogenic PRRS Live Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 89. Dahuanong Animal Health Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 91. Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 92. Dahuanong Animal Health Main Business
Table 93. Dahuanong Animal Health Latest Developments
Table 94. Zoetis Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Zoetis Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 96. Zoetis Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 97. Zoetis Main Business
Table 98. Zoetis Latest Developments
Table 99. Jilin Teyan Biotechnology Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 101. Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 102. Jilin Teyan Biotechnology Main Business
Table 103. Jilin Teyan Biotechnology Latest Developments
Table 104. Qingdao Yebio Bioengineering Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 106. Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 107. Qingdao Yebio Bioengineering Main Business
Table 108. Qingdao Yebio Bioengineering Latest Developments
Table 109. Sinopharm Yangzhou Vac Biological Engineering Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 111. Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 112. Sinopharm Yangzhou Vac Biological Engineering Main Business
Table 113. Sinopharm Yangzhou Vac Biological Engineering Latest Developments
Table 114. Pulike Biological Engineering Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 116. Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 117. Pulike Biological Engineering Main Business
Table 118. Pulike Biological Engineering Latest Developments
Table 119. Guangdong WINSUN Bio-pharmaceutical Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 121. Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 122. Guangdong WINSUN Bio-pharmaceutical Main Business
Table 123. Guangdong WINSUN Bio-pharmaceutical Latest Developments
Table 124. Sinovetah Biological Pharmaceutical Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 125. Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 126. Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 127. Sinovetah Biological Pharmaceutical Main Business
Table 128. Sinovetah Biological Pharmaceutical Latest Developments
Table 129. TECON Pharmaceutical Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 130. TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 131. TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 132. TECON Pharmaceutical Main Business
Table 133. TECON Pharmaceutical Latest Developments
Table 134. Harbin Veken Biotechnology Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 135. Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 136. Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 137. Harbin Veken Biotechnology Main Business
Table 138. Harbin Veken Biotechnology Latest Developments
Table 139. CAHIC Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 140. CAHIC Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 141. CAHIC Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 142. CAHIC Main Business
Table 143. CAHIC Latest Developments
Table 144. Huapai Biotechnology Group Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 145. Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 146. Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 147. Huapai Biotechnology Group Main Business
Table 148. Huapai Biotechnology Group Latest Developments
Table 149. Chengdu Shiji Biological Pharmaceutical Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 150. Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 151. Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 152. Chengdu Shiji Biological Pharmaceutical Main Business
Table 153. Chengdu Shiji Biological Pharmaceutical Latest Developments
Table 154. Jilin Heyuan Biotechnology Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 155. Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 156. Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 157. Jilin Heyuan Biotechnology Main Business
Table 158. Jilin Heyuan Biotechnology Latest Developments
Table 1. Highly Pathogenic PRRS Live Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Highly Pathogenic PRRS Live Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of JXA1-R Strain Live Vaccine
Table 4. Major Players of TJM-F92 Strain Live Vaccine
Table 5. Major Players of GDr180 Strain Live Vaccine
Table 6. Major Players of Others
Table 7. Global Highly Pathogenic PRRS Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 8. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Type (2021-2026)
Table 9. Global Highly Pathogenic PRRS Live Vaccine Revenue by Type (2021-2026) & ($ million)
Table 10. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Type (2021-2026)
Table 11. Global Highly Pathogenic PRRS Live Vaccine Sale Price by Type (2021-2026) & (US$/Dose)
Table 12. Major Players of Monovalent Live Vaccine
Table 13. Major Players of Combination Live Vaccine
Table 14. Global Highly Pathogenic PRRS Live Vaccine Sales by Product Combination (2021-2026) & (K Dose)
Table 15. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Product Combination (2021-2026)
Table 16. Global Highly Pathogenic PRRS Live Vaccine Revenue by Product Combination (2021-2026) & ($ million)
Table 17. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Product Combination (2021-2026)
Table 18. Global Highly Pathogenic PRRS Live Vaccine Sale Price by Product Combination (2021-2026) & (US$/Dose)
Table 19. Major Players of Small Pack (Below 20 Doses per Vial)
Table 20. Major Players of Medium Pack (20?50 Doses per Vial)
Table 21. Major Players of Large Pack (Above 50 Doses per Vial)
Table 22. Global Highly Pathogenic PRRS Live Vaccine Sales by Dose Pack Size (2021-2026) & (K Dose)
Table 23. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Dose Pack Size (2021-2026)
Table 24. Global Highly Pathogenic PRRS Live Vaccine Revenue by Dose Pack Size (2021-2026) & ($ million)
Table 25. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
Table 26. Global Highly Pathogenic PRRS Live Vaccine Sale Price by Dose Pack Size (2021-2026) & (US$/Dose)
Table 27. Global Highly Pathogenic PRRS Live Vaccine Sale by Application (2021-2026) & (K Dose)
Table 28. Global Highly Pathogenic PRRS Live Vaccine Sale Market Share by Application (2021-2026)
Table 29. Global Highly Pathogenic PRRS Live Vaccine Revenue by Application (2021-2026) & ($ million)
Table 30. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Application (2021-2026)
Table 31. Global Highly Pathogenic PRRS Live Vaccine Sale Price by Application (2021-2026) & (US$/Dose)
Table 32. Global Highly Pathogenic PRRS Live Vaccine Sales by Company (2021-2026) & (K Dose)
Table 33. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Company (2021-2026)
Table 34. Global Highly Pathogenic PRRS Live Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 35. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Company (2021-2026)
Table 36. Global Highly Pathogenic PRRS Live Vaccine Sale Price by Company (2021-2026) & (US$/Dose)
Table 37. Key Manufacturers Highly Pathogenic PRRS Live Vaccine Producing Area Distribution and Sales Area
Table 38. Players Highly Pathogenic PRRS Live Vaccine Products Offered
Table 39. Highly Pathogenic PRRS Live Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 40. New Products and Potential Entrants
Table 41. Market M&A Activity & Strategy
Table 42. Global Highly Pathogenic PRRS Live Vaccine Sales by Geographic Region (2021-2026) & (K Dose)
Table 43. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share Geographic Region (2021-2026)
Table 44. Global Highly Pathogenic PRRS Live Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 45. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 46. Global Highly Pathogenic PRRS Live Vaccine Sales by Country/Region (2021-2026) & (K Dose)
Table 47. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Country/Region (2021-2026)
Table 48. Global Highly Pathogenic PRRS Live Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 49. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 50. Americas Highly Pathogenic PRRS Live Vaccine Sales by Country (2021-2026) & (K Dose)
Table 51. Americas Highly Pathogenic PRRS Live Vaccine Sales Market Share by Country (2021-2026)
Table 52. Americas Highly Pathogenic PRRS Live Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 53. Americas Highly Pathogenic PRRS Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 54. Americas Highly Pathogenic PRRS Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 55. APAC Highly Pathogenic PRRS Live Vaccine Sales by Region (2021-2026) & (K Dose)
Table 56. APAC Highly Pathogenic PRRS Live Vaccine Sales Market Share by Region (2021-2026)
Table 57. APAC Highly Pathogenic PRRS Live Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 58. APAC Highly Pathogenic PRRS Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 59. APAC Highly Pathogenic PRRS Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 60. Europe Highly Pathogenic PRRS Live Vaccine Sales by Country (2021-2026) & (K Dose)
Table 61. Europe Highly Pathogenic PRRS Live Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 62. Europe Highly Pathogenic PRRS Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 63. Europe Highly Pathogenic PRRS Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 64. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales by Country (2021-2026) & (K Dose)
Table 65. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Country (2021-2026)
Table 66. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales by Type (2021-2026) & (K Dose)
Table 67. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales by Application (2021-2026) & (K Dose)
Table 68. Key Market Drivers & Growth Opportunities of Highly Pathogenic PRRS Live Vaccine
Table 69. Key Market Challenges & Risks of Highly Pathogenic PRRS Live Vaccine
Table 70. Key Industry Trends of Highly Pathogenic PRRS Live Vaccine
Table 71. Highly Pathogenic PRRS Live Vaccine Raw Material
Table 72. Key Suppliers of Raw Materials
Table 73. Highly Pathogenic PRRS Live Vaccine Distributors List
Table 74. Highly Pathogenic PRRS Live Vaccine Customer List
Table 75. Global Highly Pathogenic PRRS Live Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 76. Global Highly Pathogenic PRRS Live Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 77. Americas Highly Pathogenic PRRS Live Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 78. Americas Highly Pathogenic PRRS Live Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 79. APAC Highly Pathogenic PRRS Live Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 80. APAC Highly Pathogenic PRRS Live Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Europe Highly Pathogenic PRRS Live Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 82. Europe Highly Pathogenic PRRS Live Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 84. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 85. Global Highly Pathogenic PRRS Live Vaccine Sales Forecast by Type (2027-2032) & (K Dose)
Table 86. Global Highly Pathogenic PRRS Live Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 87. Global Highly Pathogenic PRRS Live Vaccine Sales Forecast by Application (2027-2032) & (K Dose)
Table 88. Global Highly Pathogenic PRRS Live Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 89. Dahuanong Animal Health Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 91. Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 92. Dahuanong Animal Health Main Business
Table 93. Dahuanong Animal Health Latest Developments
Table 94. Zoetis Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Zoetis Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 96. Zoetis Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 97. Zoetis Main Business
Table 98. Zoetis Latest Developments
Table 99. Jilin Teyan Biotechnology Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 101. Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 102. Jilin Teyan Biotechnology Main Business
Table 103. Jilin Teyan Biotechnology Latest Developments
Table 104. Qingdao Yebio Bioengineering Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 106. Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 107. Qingdao Yebio Bioengineering Main Business
Table 108. Qingdao Yebio Bioengineering Latest Developments
Table 109. Sinopharm Yangzhou Vac Biological Engineering Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 111. Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 112. Sinopharm Yangzhou Vac Biological Engineering Main Business
Table 113. Sinopharm Yangzhou Vac Biological Engineering Latest Developments
Table 114. Pulike Biological Engineering Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 116. Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 117. Pulike Biological Engineering Main Business
Table 118. Pulike Biological Engineering Latest Developments
Table 119. Guangdong WINSUN Bio-pharmaceutical Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 121. Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 122. Guangdong WINSUN Bio-pharmaceutical Main Business
Table 123. Guangdong WINSUN Bio-pharmaceutical Latest Developments
Table 124. Sinovetah Biological Pharmaceutical Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 125. Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 126. Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 127. Sinovetah Biological Pharmaceutical Main Business
Table 128. Sinovetah Biological Pharmaceutical Latest Developments
Table 129. TECON Pharmaceutical Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 130. TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 131. TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 132. TECON Pharmaceutical Main Business
Table 133. TECON Pharmaceutical Latest Developments
Table 134. Harbin Veken Biotechnology Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 135. Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 136. Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 137. Harbin Veken Biotechnology Main Business
Table 138. Harbin Veken Biotechnology Latest Developments
Table 139. CAHIC Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 140. CAHIC Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 141. CAHIC Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 142. CAHIC Main Business
Table 143. CAHIC Latest Developments
Table 144. Huapai Biotechnology Group Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 145. Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 146. Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 147. Huapai Biotechnology Group Main Business
Table 148. Huapai Biotechnology Group Latest Developments
Table 149. Chengdu Shiji Biological Pharmaceutical Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 150. Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 151. Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 152. Chengdu Shiji Biological Pharmaceutical Main Business
Table 153. Chengdu Shiji Biological Pharmaceutical Latest Developments
Table 154. Jilin Heyuan Biotechnology Basic Information, Highly Pathogenic PRRS Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 155. Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Product Portfolios and Specifications
Table 156. Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 157. Jilin Heyuan Biotechnology Main Business
Table 158. Jilin Heyuan Biotechnology Latest Developments
LIST OF FIGURES
Figure 1. Picture of Highly Pathogenic PRRS Live Vaccine
Figure 2. Highly Pathogenic PRRS Live Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Highly Pathogenic PRRS Live Vaccine Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Highly Pathogenic PRRS Live Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Highly Pathogenic PRRS Live Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Highly Pathogenic PRRS Live Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Highly Pathogenic PRRS Live Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of JXA1-R Strain Live Vaccine
Figure 12. Product Picture of TJM-F92 Strain Live Vaccine
Figure 13. Product Picture of GDr180 Strain Live Vaccine
Figure 14. Product Picture of Others
Figure 15. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Type in 2026
Figure 16. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Type (2021-2026)
Figure 17. Product Picture of Monovalent Live Vaccine
Figure 18. Product Picture of Combination Live Vaccine
Figure 19. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Product Combination in 2026
Figure 20. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Product Combination (2021-2026)
Figure 21. Product Picture of Small Pack (Below 20 Doses per Vial)
Figure 22. Product Picture of Medium Pack (20?50 Doses per Vial)
Figure 23. Product Picture of Large Pack (Above 50 Doses per Vial)
Figure 24. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Dose Pack Size in 2026
Figure 25. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
Figure 26. Highly Pathogenic PRRS Live Vaccine Consumed in Large-scale Integrated Pig Farming Groups
Figure 27. Global Highly Pathogenic PRRS Live Vaccine Market: Large-scale Integrated Pig Farming Groups (2021-2026) & (K Dose)
Figure 28. Highly Pathogenic PRRS Live Vaccine Consumed in Breeding and Multiplier Farms
Figure 29. Global Highly Pathogenic PRRS Live Vaccine Market: Breeding and Multiplier Farms (2021-2026) & (K Dose)
Figure 30. Highly Pathogenic PRRS Live Vaccine Consumed in Animal Disease Control Institutions
Figure 31. Global Highly Pathogenic PRRS Live Vaccine Market: Animal Disease Control Institutions (2021-2026) & (K Dose)
Figure 32. Highly Pathogenic PRRS Live Vaccine Consumed in Others
Figure 33. Global Highly Pathogenic PRRS Live Vaccine Market: Others (2021-2026) & (K Dose)
Figure 34. Global Highly Pathogenic PRRS Live Vaccine Sale Market Share by Application (2025)
Figure 35. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Application in 2025
Figure 36. Highly Pathogenic PRRS Live Vaccine Sales by Company in 2025 (K Dose)
Figure 37. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Company in 2025
Figure 38. Highly Pathogenic PRRS Live Vaccine Revenue by Company in 2025 ($ millions)
Figure 39. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Company in 2025
Figure 40. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 41. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Geographic Region in 2025
Figure 42. Americas Highly Pathogenic PRRS Live Vaccine Sales 2021-2026 (K Dose)
Figure 43. Americas Highly Pathogenic PRRS Live Vaccine Revenue 2021-2026 ($ millions)
Figure 44. APAC Highly Pathogenic PRRS Live Vaccine Sales 2021-2026 (K Dose)
Figure 45. APAC Highly Pathogenic PRRS Live Vaccine Revenue 2021-2026 ($ millions)
Figure 46. Europe Highly Pathogenic PRRS Live Vaccine Sales 2021-2026 (K Dose)
Figure 47. Europe Highly Pathogenic PRRS Live Vaccine Revenue 2021-2026 ($ millions)
Figure 48. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales 2021-2026 (K Dose)
Figure 49. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Revenue 2021-2026 ($ millions)
Figure 50. Americas Highly Pathogenic PRRS Live Vaccine Sales Market Share by Country in 2025
Figure 51. Americas Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Country (2021-2026)
Figure 52. Americas Highly Pathogenic PRRS Live Vaccine Sales Market Share by Type (2021-2026)
Figure 53. Americas Highly Pathogenic PRRS Live Vaccine Sales Market Share by Application (2021-2026)
Figure 54. United States Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. Canada Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Mexico Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. Brazil Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. APAC Highly Pathogenic PRRS Live Vaccine Sales Market Share by Region in 2025
Figure 59. APAC Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Region (2021-2026)
Figure 60. APAC Highly Pathogenic PRRS Live Vaccine Sales Market Share by Type (2021-2026)
Figure 61. APAC Highly Pathogenic PRRS Live Vaccine Sales Market Share by Application (2021-2026)
Figure 62. China Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. Japan Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. South Korea Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Southeast Asia Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. India Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. Australia Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 68. China Taiwan Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. Europe Highly Pathogenic PRRS Live Vaccine Sales Market Share by Country in 2025
Figure 70. Europe Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Country (2021-2026)
Figure 71. Europe Highly Pathogenic PRRS Live Vaccine Sales Market Share by Type (2021-2026)
Figure 72. Europe Highly Pathogenic PRRS Live Vaccine Sales Market Share by Application (2021-2026)
Figure 73. Germany Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. France Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. UK Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 76. Italy Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 77. Russia Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 78. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Market Share by Country (2021-2026)
Figure 79. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Market Share by Type (2021-2026)
Figure 80. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Market Share by Application (2021-2026)
Figure 81. Egypt Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 82. South Africa Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 83. Israel Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 84. Turkey Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 85. GCC Countries Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 86. Manufacturing Cost Structure Analysis of Highly Pathogenic PRRS Live Vaccine in 2026
Figure 87. Manufacturing Process Analysis of Highly Pathogenic PRRS Live Vaccine
Figure 88. Industry Chain Structure of Highly Pathogenic PRRS Live Vaccine
Figure 89. Channels of Distribution
Figure 90. Global Highly Pathogenic PRRS Live Vaccine Sales Market Forecast by Region (2027-2032)
Figure 91. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 92. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 93. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 94. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 95. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Highly Pathogenic PRRS Live Vaccine
Figure 2. Highly Pathogenic PRRS Live Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Highly Pathogenic PRRS Live Vaccine Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Highly Pathogenic PRRS Live Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Highly Pathogenic PRRS Live Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Highly Pathogenic PRRS Live Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Highly Pathogenic PRRS Live Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of JXA1-R Strain Live Vaccine
Figure 12. Product Picture of TJM-F92 Strain Live Vaccine
Figure 13. Product Picture of GDr180 Strain Live Vaccine
Figure 14. Product Picture of Others
Figure 15. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Type in 2026
Figure 16. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Type (2021-2026)
Figure 17. Product Picture of Monovalent Live Vaccine
Figure 18. Product Picture of Combination Live Vaccine
Figure 19. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Product Combination in 2026
Figure 20. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Product Combination (2021-2026)
Figure 21. Product Picture of Small Pack (Below 20 Doses per Vial)
Figure 22. Product Picture of Medium Pack (20?50 Doses per Vial)
Figure 23. Product Picture of Large Pack (Above 50 Doses per Vial)
Figure 24. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Dose Pack Size in 2026
Figure 25. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Dose Pack Size (2021-2026)
Figure 26. Highly Pathogenic PRRS Live Vaccine Consumed in Large-scale Integrated Pig Farming Groups
Figure 27. Global Highly Pathogenic PRRS Live Vaccine Market: Large-scale Integrated Pig Farming Groups (2021-2026) & (K Dose)
Figure 28. Highly Pathogenic PRRS Live Vaccine Consumed in Breeding and Multiplier Farms
Figure 29. Global Highly Pathogenic PRRS Live Vaccine Market: Breeding and Multiplier Farms (2021-2026) & (K Dose)
Figure 30. Highly Pathogenic PRRS Live Vaccine Consumed in Animal Disease Control Institutions
Figure 31. Global Highly Pathogenic PRRS Live Vaccine Market: Animal Disease Control Institutions (2021-2026) & (K Dose)
Figure 32. Highly Pathogenic PRRS Live Vaccine Consumed in Others
Figure 33. Global Highly Pathogenic PRRS Live Vaccine Market: Others (2021-2026) & (K Dose)
Figure 34. Global Highly Pathogenic PRRS Live Vaccine Sale Market Share by Application (2025)
Figure 35. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Application in 2025
Figure 36. Highly Pathogenic PRRS Live Vaccine Sales by Company in 2025 (K Dose)
Figure 37. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Company in 2025
Figure 38. Highly Pathogenic PRRS Live Vaccine Revenue by Company in 2025 ($ millions)
Figure 39. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Company in 2025
Figure 40. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 41. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Geographic Region in 2025
Figure 42. Americas Highly Pathogenic PRRS Live Vaccine Sales 2021-2026 (K Dose)
Figure 43. Americas Highly Pathogenic PRRS Live Vaccine Revenue 2021-2026 ($ millions)
Figure 44. APAC Highly Pathogenic PRRS Live Vaccine Sales 2021-2026 (K Dose)
Figure 45. APAC Highly Pathogenic PRRS Live Vaccine Revenue 2021-2026 ($ millions)
Figure 46. Europe Highly Pathogenic PRRS Live Vaccine Sales 2021-2026 (K Dose)
Figure 47. Europe Highly Pathogenic PRRS Live Vaccine Revenue 2021-2026 ($ millions)
Figure 48. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales 2021-2026 (K Dose)
Figure 49. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Revenue 2021-2026 ($ millions)
Figure 50. Americas Highly Pathogenic PRRS Live Vaccine Sales Market Share by Country in 2025
Figure 51. Americas Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Country (2021-2026)
Figure 52. Americas Highly Pathogenic PRRS Live Vaccine Sales Market Share by Type (2021-2026)
Figure 53. Americas Highly Pathogenic PRRS Live Vaccine Sales Market Share by Application (2021-2026)
Figure 54. United States Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. Canada Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Mexico Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. Brazil Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. APAC Highly Pathogenic PRRS Live Vaccine Sales Market Share by Region in 2025
Figure 59. APAC Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Region (2021-2026)
Figure 60. APAC Highly Pathogenic PRRS Live Vaccine Sales Market Share by Type (2021-2026)
Figure 61. APAC Highly Pathogenic PRRS Live Vaccine Sales Market Share by Application (2021-2026)
Figure 62. China Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. Japan Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. South Korea Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Southeast Asia Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. India Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. Australia Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 68. China Taiwan Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. Europe Highly Pathogenic PRRS Live Vaccine Sales Market Share by Country in 2025
Figure 70. Europe Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Country (2021-2026)
Figure 71. Europe Highly Pathogenic PRRS Live Vaccine Sales Market Share by Type (2021-2026)
Figure 72. Europe Highly Pathogenic PRRS Live Vaccine Sales Market Share by Application (2021-2026)
Figure 73. Germany Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. France Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. UK Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 76. Italy Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 77. Russia Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 78. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Market Share by Country (2021-2026)
Figure 79. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Market Share by Type (2021-2026)
Figure 80. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Market Share by Application (2021-2026)
Figure 81. Egypt Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 82. South Africa Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 83. Israel Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 84. Turkey Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 85. GCC Countries Highly Pathogenic PRRS Live Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 86. Manufacturing Cost Structure Analysis of Highly Pathogenic PRRS Live Vaccine in 2026
Figure 87. Manufacturing Process Analysis of Highly Pathogenic PRRS Live Vaccine
Figure 88. Industry Chain Structure of Highly Pathogenic PRRS Live Vaccine
Figure 89. Channels of Distribution
Figure 90. Global Highly Pathogenic PRRS Live Vaccine Sales Market Forecast by Region (2027-2032)
Figure 91. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 92. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 93. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 94. Global Highly Pathogenic PRRS Live Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 95. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share Forecast by Application (2027-2032)
